JP5401733B2 - プロバイオティクス及びシンバイオティックとしてのラクトバチルス・ケフィラノファシエンス（Ｌａｃｔｏｂａｃｉｌｌｕｓｋｅｆｉｒａｎｏｆａｃｉｅｎｓ）の使用 - Google Patents

プロバイオティクス及びシンバイオティックとしてのラクトバチルス・ケフィラノファシエンス（Ｌａｃｔｏｂａｃｉｌｌｕｓｋｅｆｉｒａｎｏｆａｃｉｅｎｓ）の使用 Download PDF

Info

Publication number
JP5401733B2
JP5401733B2 JP2007554405A JP2007554405A JP5401733B2 JP 5401733 B2 JP5401733 B2 JP 5401733B2 JP 2007554405 A JP2007554405 A JP 2007554405A JP 2007554405 A JP2007554405 A JP 2007554405A JP 5401733 B2 JP5401733 B2 JP 5401733B2
Authority
JP
Japan
Prior art keywords
kefiranofaciens
accession number
lactobacillus
group
idac accession
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2007554405A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008530034A5 (https=
JP2008530034A (ja
Inventor
ルミュー，ピエール
プレクール，ルイ−フィリップ
シマール，エリック
Original Assignee
バイオラクティス インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオラクティス インコーポレイティド filed Critical バイオラクティス インコーポレイティド
Publication of JP2008530034A publication Critical patent/JP2008530034A/ja
Publication of JP2008530034A5 publication Critical patent/JP2008530034A5/ja
Application granted granted Critical
Publication of JP5401733B2 publication Critical patent/JP5401733B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF
    • A23C21/00—Whey; Whey preparations
    • A23C21/02—Whey; Whey preparations containing, or treated with, microorganisms or enzymes
    • A23C21/026—Whey; Whey preparations containing, or treated with, microorganisms or enzymes containing, or treated only with, lactic acid producing bacteria, bifidobacteria or propionic acid bacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
    • A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
JP2007554405A 2005-02-11 2006-02-10 プロバイオティクス及びシンバイオティックとしてのラクトバチルス・ケフィラノファシエンス（Ｌａｃｔｏｂａｃｉｌｌｕｓｋｅｆｉｒａｎｏｆａｃｉｅｎｓ）の使用 Expired - Fee Related JP5401733B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65165705P 2005-02-11 2005-02-11
US60/651,657 2005-02-11
PCT/CA2006/000206 WO2006084381A1 (en) 2005-02-11 2006-02-10 Use of lactobacillus kefiranofaciens as a probiotic and a synbiotic

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013044197A Division JP2013139462A (ja) 2005-02-11 2013-03-06 プロバイオティクス及びシンバイオティックとしてのラクトバチルス・ケフィラノファシエンス（Ｌａｃｔｏｂａｃｉｌｌｕｓｋｅｆｉｒａｎｏｆａｃｉｅｎｓ）の使用

Publications (3)

Publication Number Publication Date
JP2008530034A JP2008530034A (ja) 2008-08-07
JP2008530034A5 JP2008530034A5 (https=) 2012-09-13
JP5401733B2 true JP5401733B2 (ja) 2014-01-29

Family

ID=36792883

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007554405A Expired - Fee Related JP5401733B2 (ja) 2005-02-11 2006-02-10 プロバイオティクス及びシンバイオティックとしてのラクトバチルス・ケフィラノファシエンス（Ｌａｃｔｏｂａｃｉｌｌｕｓｋｅｆｉｒａｎｏｆａｃｉｅｎｓ）の使用
JP2013044197A Pending JP2013139462A (ja) 2005-02-11 2013-03-06 プロバイオティクス及びシンバイオティックとしてのラクトバチルス・ケフィラノファシエンス（Ｌａｃｔｏｂａｃｉｌｌｕｓｋｅｆｉｒａｎｏｆａｃｉｅｎｓ）の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013044197A Pending JP2013139462A (ja) 2005-02-11 2013-03-06 プロバイオティクス及びシンバイオティックとしてのラクトバチルス・ケフィラノファシエンス（Ｌａｃｔｏｂａｃｉｌｌｕｓｋｅｆｉｒａｎｏｆａｃｉｅｎｓ）の使用

Country Status (8)

Country Link
US (2) US20090130072A1 (https=)
EP (1) EP1853284B1 (https=)
JP (2) JP5401733B2 (https=)
CA (1) CA2597229A1 (https=)
DK (1) DK1853284T3 (https=)
ES (1) ES2496965T3 (https=)
MX (1) MX2007009659A (https=)
WO (1) WO2006084381A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008214253A (ja) * 2007-03-02 2008-09-18 Snow Brand Milk Prod Co Ltd 内臓脂肪減少剤
US20110002994A1 (en) * 2007-10-02 2011-01-06 Institut National De La Recherche Scientifique Method of regulating the th17 pathway and its associated metabolic impact
JP2010037225A (ja) * 2008-08-01 2010-02-18 Nippon Kefia Kk 乳清ケフィアを有効成分として含んでなる体脂肪減少剤
JP2012034616A (ja) * 2010-08-06 2012-02-23 Umeya Co Ltd 塩たらこの製造方法及び塩たらこ、並びに辛子明太子の製造方法及び辛子明太子
JP5840368B2 (ja) 2011-02-02 2016-01-06 カルピス株式会社 関節炎予防改善用物質
KR101779719B1 (ko) 2016-08-30 2017-09-19 건국대학교 산학협력단 신규한 락토바실러스 케피아노파시엔스 dn1 균주 및 이를 포함하는 변비의 예방 또는 치료용 조성물
CN106937745A (zh) * 2016-08-31 2017-07-11 快醒生物科技（北京）有限公司 一种具有改善肠道功能的保健品及其制备方法
JP7482494B2 (ja) * 2016-11-01 2024-05-14 慶應義塾 Ｔｈ１細胞を誘導する細菌
KR102089938B1 (ko) * 2016-12-21 2020-03-17 (주)프로스테믹스 케피어 그레인 유래 미세소포체의 용도
KR101930143B1 (ko) * 2016-12-21 2018-12-17 건국대학교 산학협력단 유산균 유래 세포외다당류를 함유하는 항균 조성물
JP7542798B2 (ja) * 2017-08-10 2024-09-02 株式会社Ｎｒｌファーマ 妊娠中の母子の健康状態改善剤
US10632161B1 (en) 2019-05-23 2020-04-28 Prostemics Co. Ltd. Method for ameliorating or treating a bowel disease
CN111575202A (zh) * 2020-05-19 2020-08-25 北京科拓恒通生物技术股份有限公司 一株用于预防辅助治疗ⅱ型糖尿病的干酪乳杆菌及其应用
CN111808910A (zh) * 2020-07-22 2020-10-23 南京农业大学 一种评价膳食多糖活性的方法
KR20220061555A (ko) * 2020-11-06 2022-05-13 (주)프로스테믹스 신규한 락토바실러스 속 균주 및 상기 균주 유래 세포외 소포의 용도
JP7696856B2 (ja) * 2022-03-31 2025-06-23 よつ葉乳業株式会社 ケフィアグレイン類似物の作出方法並びにケフィアグレイン類似物を用いた発酵乳の製造方法
CN114805474B (zh) * 2022-04-02 2024-03-22 中国海洋大学 一株干酪乳杆菌fn345及其在制备预防辅食期婴儿腹泻菌剂中的应用
CN116948916B (zh) * 2023-08-11 2024-06-11 四川大学 一种干酪乳杆菌及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55113718A (en) * 1979-02-27 1980-09-02 Yakult Honsha Co Ltd Antitumor agent
JPH05301812A (ja) * 1992-04-23 1993-11-16 Sansho Seiyaku Co Ltd 皮膚外用剤
JP4580542B2 (ja) * 2000-05-17 2010-11-17 株式會社バイオニア 肥満又は糖尿病治療用微生物及びその微生物を含む医薬組成物
US20020182274A1 (en) * 2001-03-21 2002-12-05 Kung-Ming Lu Methods for inhibiting cancer growth, reducing infection and promoting general health with a fermented soy extract
JP2002330798A (ja) * 2001-05-11 2002-11-19 Yamato Yakuhin Kk 多糖製造方法
ES2451618T3 (es) * 2001-12-20 2014-03-28 Biolactis Inc. Matriz de proteína maleable y usos de estas

Also Published As

Publication number Publication date
EP1853284A4 (en) 2012-03-21
ES2496965T3 (es) 2014-09-22
MX2007009659A (es) 2008-01-16
EP1853284B1 (en) 2014-04-09
WO2006084381A1 (en) 2006-08-17
JP2013139462A (ja) 2013-07-18
US20090130072A1 (en) 2009-05-21
DK1853284T3 (da) 2014-07-14
EP1853284A1 (en) 2007-11-14
US20140193383A1 (en) 2014-07-10
JP2008530034A (ja) 2008-08-07
CA2597229A1 (en) 2006-08-17

Similar Documents

Publication Publication Date Title
JP2013139462A (ja) プロバイオティクス及びシンバイオティックとしてのラクトバチルス・ケフィラノファシエンス（Ｌａｃｔｏｂａｃｉｌｌｕｓｋｅｆｉｒａｎｏｆａｃｉｅｎｓ）の使用
CN108289918B (zh) 经巴氏灭菌的艾克曼菌用于治疗代谢病症的用途
EP2615163B1 (en) Composition comprising probiotics having aryl hydrocarbon receptor activating potency for use as anti-inflammatory agents
EP2179028B1 (en) A novel strain of bifidobacterium and active peptides against rotavirus infections
US20200323930A1 (en) Strain of lactobacillus acidophilus having analgesic properties in the gastrointestinal system
JP4200518B2 (ja) 代謝症候群に関与する危険因子を減少するＬａｃｔｏｂａｃｉｌｌｕｓ株の使用
JP4942831B2 (ja) 抗アレルギー用組成物
CN103619343A (zh) 双歧杆菌cect7765及其在预防和/或治疗超重、肥胖和相关病理中的用途
TW200944215A (en) Lactobacillus isolates having anti-inflammatory activities and uses of the same
EP2935560A1 (en) Use of bifidobacterium animalis for treating or preventing body weight gain and insulin resistance
WO2019156251A1 (ja) リポ多糖制御性腸内細菌及びその用途
CN117165497A (zh) 一种改善便秘的植物乳植杆菌Lp18及其应用和产品
JPWO2020054728A1 (ja) Ｐａｒａｐｒｅｖｏｔｅｌｌａ属に属する細菌を有効成分として含有する、トリプシン活性を抑制するための組成物
CN103874428B (zh) 解木聚糖拟杆菌物种微生物
CN103987839B (zh) 能够抑制幽门螺杆菌菌株粘附至上皮细胞的新德式乳杆菌保加利亚亚种菌株
IL295991A (en) Coprococcus bacteria for use in the treatment of metabolic syndrome and inflammatory bowel diseases
CN111132684A (zh) 作为生物治疗药物的血孪生球菌
CN116410884A (zh) 乳杆菌及其用途
Karaffová et al. Mudro nová
WO2024203934A1 (ja) 腸内細菌叢改善用組成物
Class et al. Patent application title: Use of Bifidobacterium Animalis for Treating or Preventing Body Weight Gain and Insulin Resistance Inventors: Jian Shen (Shanghai, CN) Jingjing Wang (Shanghai, CN) Liping Zhao (Shanghai, CN) Martin Saul Obin (West Newton, MA, US) Muriel Derrien (Bures Sur Yvette, FR) Emilie Rocher (Massy, FR) Johan Van Hylckama Vlieg (Marly Le Roi, FR) Assignees: TUFTS UNIVERSITY COMPAGNIE GERVAIS DANONE
Singh Evaluation of Probiotic Attributes of Dairy Starter Cultures Using Various Test Methods

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090210

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090210

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120124

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120424

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120502

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20120724

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20121106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130306

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20130606

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130709

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130718

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130813

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130912

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130924

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20131009

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131011

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20131009

LAPS Cancellation because of no payment of annual fees